A PILOT TRIAL OF GEMCITABINE IN COMBINATION WITH CAPECITABINE OR ERLOTINIB COMPARED TO GEMCITABINE ALONE IN PATIENTS WITH ADVANCED PANCREATIC CANCER

被引：0

作者：

Cho, J. Y. ^{[1
]}

Lim, J. Y. ^{[1
]}

Lee, S. J. ^{[1
]}

Lee, D. K. ^{[1
]}

Park, J. S. ^{[1
]}

Yoon, D. S. ^{[1
]}

Min, Y. H. ^{[2
]}

机构：

[1] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Seoul, South Korea

[2] Severance Hosp, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：240 / 240

页数：1

共 50 条

[31] The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer
Irie, Kuniyasu
Ueno, Makoto
Kobayashi, Satoshi
Gouda, Yoshihiro
Ohkawa, Shinichi
Manabu, Morimoto
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[32] Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
Boeck, Stefan
Wilkowski, Ralf
Bruns, Christiane J.
Issels, Rolf D.
Schulz, Christoph
Moosmann, Nicolas
Laessig, Dorit
Haas, Michael
Golf, Alexander
Heinemann, Volker
ONCOLOGY, 2007, 73 (3-4) : 221 - 227
[33] A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
Sanghvi, Samrat M.
Coffman, Alex R.
Hsueh, Chung-Tsen
Kang, Joseph
Park, Annie
Solomon, Naveenraj L.
Garberoglio, Carlos A.
Reeves, Mark E.
Slater, Jerry D.
Yang, Gary Y.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1989 - 1996
[34] Efficiency of gemcitabine and capecitabine in the treatment of advanced pancreatic cancer
Zeynalov, R.
Musayev, I
Giyasbeyli, S.
Gasanzadeh, J.
Dadashova, N.
Ahadova, N.
ANNALS OF ONCOLOGY, 2007, 18 : VII117 - VII117
[35] Comparison of the efficacy of gemcitabine with capecitabine and gemcitabine with erlotinib combination chemotherapy in recurrent or advanced pancreatic cancer as first-line treatment: Single-center experience
Chun, S.
Lee, M.
Jeon, E.
An, H.
Hong, T.
You, Y.
Kim, D.
Lee, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[36] Gemcitabine plus capecitabine is effective in advanced pancreatic cancer
Nature Clinical Practice Oncology, 2007, 4 (9): : 504 - 504
[37] Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (Reprinted from vol 25, 1960, 2007)
Moore, Malcolm J.
Goldstein, David
Hamm, John
Figer, Arie
Hecht, Joel R.
Gallinger, Steven
Au, Heather J.
Murawa, Pawel
Walde, David
Wolff, Robert A.
Campos, Daniel
Lim, Robert
Ding, Keyue
Clark, Gary
Voskoglou-Nomikos, Theodora
Ptasynski, Mieke
Parulekar, Wendy
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4714 - 4720
[38] Phase I trial of capecitabine and gemcitabine with radiotherapy in locally advanced pancreatic cancer
Leong, T.
Michael, M.
Price, T.
Ganju, V
Strickland, A.
Jefford, M.
Muller, A.
Ngan, S.
Milner, A.
Zalcberg, J.
ANNALS OF ONCOLOGY, 2006, 17 : 34 - 34
[39] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, David
Chau, Ian
Stocken, Deborah D.
Valle, Juan W.
Smith, David
Steward, William
Harper, Peter G.
Dunn, Janet
Tudur-Smith, Catrin
West, Julia
Falk, Stephen
Crellin, Adrian
Adab, Fawzi
Thompson, Joyce
Leonard, Pauline
Ostrowski, Joe
Eatock, Martin
Scheithauer, Werner
Herrmann, Richard
Neoptolemos, John P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518
[40] Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer
Eun Kyoung Jeon
Hye-Sung Won
Yoon-Ho Ko
In Seok Lee
Tae Ho Hong
Young Kyoung You
Myung Ah Lee
Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1625 - 1630

← 1 2 3 4 5 →